home / stock / vygr / vygr news


VYGR News and Press, Voyager Therapeutics Inc. From 05/13/24

Stock Information

Company Name: Voyager Therapeutics Inc.
Stock Symbol: VYGR
Market: NASDAQ
Website: voyagertherapeutics.com

Menu

VYGR VYGR Quote VYGR Short VYGR News VYGR Articles VYGR Message Board
Get VYGR Alerts

News, Short Squeeze, Breakout and More Instantly...

VYGR - INFN, VYGR and AMSC are among after hour movers

2024-05-13 17:06:07 ET Gainers: Harrow ( HROW ) +15% . Fulcrum Therapeutics ( FULC ) +7% . Allogene Therapeutics ( ALLO ) +6% . Infinera Corporation ( INFN ) +6% . Voyager Therapeutics ( VYGR ) +5% . Losers: Akoya BioScie...

VYGR - Voyager Therapeutics GAAP EPS of -$0.20 beats by $0.24, revenue of $19.5M beats by $10.02M

2024-05-13 16:04:23 ET More on Voyager Therapeutics Voyager Therapeutics: On Track To Deliver High Returns On Investment Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier Voyager Therapeutics, Inc. (VYGR) Q4 2023 Earnings Call Transcr...

VYGR - Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

- Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose trial in the coming weeks - - Development candidates selected for Neurocrine-partnered GBA1 and Friedreich ...

VYGR - Expected US Company Earnings on Monday, May 13th, 2024

Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...

VYGR - Voyager Therapeutics Presents Data for Second-Generation, TRACER(TM)-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding - - Preclinical safety and efficacy demonstrated in Alzheimer’s disease and ALS gene therapies; low IV doses pro...

VYGR - Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report first quarter 2024 financial and operating results after market close on Monday, May 13, 2024. Subseq...

VYGR - When the Price of (VYGR) Talks, People Listen

2024-05-05 08:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

VYGR - Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data related to its TRACER™ capsid discovery platform and TRACER-driven...

VYGR - Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development can...

VYGR - (VYGR) Pivots Trading Plans and Risk Controls

2024-03-16 15:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Previous 10 Next 10